Investment and Placing of Shares

EDX Medical Group plc ("EDX Medical" or the "Company"), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces that the Board of the Company has today approved the issue of 12,966,667 new ordinary shares of 1p each in the Company ("Ordinary Shares") at a price of 12p per share (the "Subscription", "Subscription Shares") to raise £1.56 million for the Company. Subscribers include both institutional and retail investors.

The Subscription completes a fund-raising round that has raised £5.7million, in aggregate, at 12p per share, following the Company's announcement on 4 February of a placing of shares to raise £4.01 million. Funds raised through these two issues will be used to support the acceleration of the development of products to help meet global demand from healthcare providers delivering personalIsed treatments.

Application has been made for the Subscription Shares to be admitted to trading on the AQSE Growth Market ("Admission") and the Subscription remains conditional on Admission. Admission is expected to take place on 4 March 2024.

Professor Sir Chris Evans, OBE, founder of EDX Medical, commented: "I am delighted by the tremendous support from institutions which have subscribed to this share issue, as well as the commitment previously from existing key shareholders. These investors see the Company as being at the forefront of diagnostic innovation at a time of increasing global demand. This round of fund-raising exceeded our expectations in terms of capital raised and the Company is well equipped to press on with development of our product portfolio."

Dr Mike Hudson, Chief Executive Officer of EDX Medical, commented: "The demand for innovative personalised treatments grows by the day and this new investment will enable the Company to accelerate our programme of clinical diagnostic products and technologies for the benefit of patients."

Total Voting Rights

The directors of EDX Medical accept responsibility for the contents of this announcement.